Trial Profile
A Pilot Study of Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy for Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2023
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary) ; Pembrolizumab (Primary) ; Yttrium-90 (Primary)
- Indications Liver metastases; Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 15 Nov 2023 Planned End Date changed from 31 Dec 2025 to 31 May 2026.
- 15 Nov 2023 Planned primary completion date changed from 30 Sep 2023 to 31 May 2024.
- 15 Aug 2023 Planned primary completion date changed from 31 Dec 2023 to 30 Sep 2023.